Is BHRT safe? What do doctors say about bioidentical hormones?

Short answer: bioidentical hormone therapy (BHRT) can be effective for menopausal symptoms, but “safe” depends on the specific product, the dose, your health risks, and who’s supervising treatment. Most doctors say: use FDA‑approved hormones when possible, treat based on individual risk/benefit, and be cautious about compounded products that make broad “natural” safety claims.

What “BHRT” means

• “Bioidentical” means the hormone molecule is chemically identical to human hormones (e.g., micronized estradiol, micronized progesterone).
• BHRT is offered as FDA‑approved products (estradiol, micronized progesterone like Prometrium) and as custom‑compounded formulations (creams, gels, pellets). The difference matters for safety oversight and evidence.

What major medical groups and the FDA say (summary)

• The American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society and the North American Menopause Society (NAMS) generally:
  • Support hormone therapy for women who have bothersome menopausal symptoms when benefits outweigh risks.
  • Advise using FDA‑approved hormone products when possible.
  • Warn that compounded BHRT products may be inconsistent in strength, purity and dosing and that claims of superior safety are not supported by solid evidence.
• The FDA has issued consumer warnings about compounded “bioidentical” hormones for these same reasons.

Evidence on benefits and risks

• Benefits: FDA‑approved estrogen (with progesterone if you have a uterus) is the most effective treatment for vasomotor symptoms (hot flashes/night sweats) and can protect bone density.
• Risks depend on age, time since menopause, route of delivery, and hormone type:
  • For many recently menopausal women (<60 or within ~10 years of menopause) short‑term HRT can have a favorable benefit/risk for symptom relief.
  • Older women or those who start hormones long after menopause show greater risks (data from the Women’s Health Initiative and follow‑up studies), including small increases in breast cancer risk (especially with combined estrogen+progestin), stroke, heart disease and venous thromboembolism (VTE).
  • Transdermal estradiol (patch or gel) appears to carry a lower risk of VTE than oral estrogen in some studies.
  • Micronized progesterone (Prometrium) may have a different side‑effect and possibly lower cardiovascular/breast risk profile versus some synthetic progestins, though data are not definitive.

Concerns about compounded BHRT

• Compounded creams, lozenges, or “pellets” are not FDA‑approved, can vary in dose and purity, and lack large controlled trials proving safety or superiority.
• Claims like “custom‑tested saliva hormone levels” or “totally natural so no side effects” are not reliable. Saliva testing is not considered a validated method to guide dosing.

Practical guidance — what doctors usually recommend

• See a qualified clinician (a board‑certified gynecologist, endocrinologist, or a menopause specialist) for a thorough history and risk assessment.
• Prefer FDA‑approved preparations when possible: for example
  • Estradiol patches (Vivelle‑Dot, Climara) or gels (EstroGel/Divigel) for transdermal delivery (lower VTE risk).
  • Oral estradiol (Estrace) if appropriate.
  • Micronized progesterone (Prometrium) for endometrial protection if you have a uterus.
  • For local vaginal symptoms, approved local products such as estradiol vaginal ring (Estring), tablets, or low‑dose creams are effective with lower systemic exposure.
• If considering compounded BHRT, use a reputable, accredited compounding pharmacy (look for PCAB accreditation) and discuss why an FDA‑approved product can’t be used.
• Use the lowest effective dose for the shortest time necessary and reassess periodically. Follow routine screening (mammograms, blood pressure, etc.) and monitor for red flags (breast changes, leg swelling/pain, chest pain).

Special notes

• Testosterone for women is not widely FDA‑approved for low libido in the U.S.; some formulations are used off‑label or compounded and require careful monitoring because of limited data.
• For milder symptoms or if hormones are contraindicated, effective nonhormonal options include certain SSRIs/SNRIs, gabapentin, clonidine and lifestyle measures.

If you’re considering BHRT

• Ask your prescriber: Are you using an FDA‑approved product or a compounded one? Why this choice? What exact dose and route? What are my risks (breast cancer, clotting, heart disease) and what monitoring will you do?
• If you want help finding a clinician, look for a menopause specialist or a clinic affiliated with a medical center, or use the NAMS “Find a Provider” resource.

If you want, tell me your age, symptoms, medical history (personal/family clotting, breast cancer, heart disease, smoking), and whether you currently take any hormones — I can give more specific guidance about risks and options.